O
O Hansen
Researcher at Novo Nordisk
Publications - 4
Citations - 3869
O Hansen is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Semaglutide & Randomized controlled trial. The author has an hindex of 4, co-authored 4 publications receiving 2824 citations.
Papers
More filters
Journal ArticleDOI
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P. Marso,Stephen C. Bain,A. Consoli,Freddy G. Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,O Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll +14 more
TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.
Journal ArticleDOI
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Melanie J. Davies,Thomas R. Pieber,Marie-Louise Hartoft-Nielsen,O Hansen,Serge Jabbour,Julio Rosenstock +5 more
TL;DR: Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks, and support phase 3 studies to assess longer-term and clinical outcomes, as well as safety.
Journal ArticleDOI
Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide
Vivian Fonseca,Matthew Capehorn,Satish K. Garg,Esteban Jódar Gimeno,O Hansen,Anders G. Holst,Gurudutt Nayak,Jochen Seufert +7 more
TL;DR: Semaglutide consistently reduced BW and IR in subjects with T2D in SUSTAIN 1-3 and IR improvement was positively associated with, and primarily mediated by, the effect of semag lutide on BW.
Journal ArticleDOI
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme
J. Hans DeVries,Cyrus Desouza,Srikanth Bellary,Jeffrey Unger,O Hansen,Jeppe Zacho,Vincent Woo +6 more
TL;DR: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects.